Abstract
AMP-activated protein kinase (AMPK) is a promising therapeutic target for cancer, type II diabetes, and other illnesses characterized by abnormal energy utilization. During the last decade, numerous labs have published a range of methods for identifying novel AMPK modulators. The current understanding of AMPK structure and regulation, however, has propelled a paradigm shift in which many researchers now consider ADP to be an additional regulatory nucleotide of AMPK. How can the AMPK community apply this new understanding of AMPK signaling to translational research? Recent insights into AMPK structure, regulation, and holoenzyme-sensitive signaling may provide the hindsight needed to clearly evaluate the strengths and weaknesses of past AMPK drug discovery efforts. Improving future strategies for AMPK drug discovery will require pairing the current understanding of AMPK signaling with improved experimental designs.
Original language | English (US) |
---|---|
Pages (from-to) | 111-118 |
Number of pages | 8 |
Journal | Pharmacology and Therapeutics |
Volume | 143 |
Issue number | 1 |
DOIs | |
State | Published - Jul 2014 |
Externally published | Yes |
Keywords
- AMPK
- Dephosphorylation inhibition
- Drug discovery
- High-throughput screening
- Nucleotide analogs
- Regulatory fragment
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)